ECCS 50

Drug Profile

ECCS 50

Alternative Names: Adipose-derived stem and regenerative cell (ADRC) therapy - Cytori Therapeutics; Adipose-derived stem cells - Cytori Therapeutics; ADRCs - Cytori Therapeutics; Cytori Cell Therapy; ECCI 50; ECCO-50; ECCS-50; Habeo; Habeo Cell Therapy

Latest Information Update: 09 Dec 2016

Price : $50

At a glance

  • Originator Cytori Therapeutics
  • Developer Assistance Publique - Hopitaux de Marseille
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Raynaud's disease; Scleroderma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Scleroderma

Most Recent Events

  • 05 Dec 2016 Additional three-year follow-up efficacy data from the phase III SCLERADEC-I trial in Scleroderma released by Cytori Therapeutics
  • 29 Nov 2016 Additional long-term efficacy data from the phase III SCLERADEC-I trial in Scleroderma released by Cytori Therapeutics
  • 24 Nov 2016 Cytori has patent protection for the use of adipose-derived cells for restoring tears in cartilage such as those present in osteoarthritic joints in European Union before November 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top